68 related articles for article (PubMed ID: 7584496)
1. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates.
Chisholm PL; Williams CA; Jones WE; Majeau GR; Oleson FB; Burrus-Fischer B; Meier W; Hochman PS
Ther Immunol; 1994 Aug; 1(4):205-16. PubMed ID: 7584496
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice.
Majeau GR; Meier W; Jimmo B; Kioussis D; Hochman PS
J Immunol; 1994 Mar; 152(6):2753-67. PubMed ID: 7511625
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers.
Meier W; Gill A; Rogge M; Dabora R; Majeau GR; Oleson FB; Jones WE; Frazier D; Miatkowski K; Hochman PS
Ther Immunol; 1995 Jun; 2(3):159-71. PubMed ID: 8885134
[TBL] [Abstract][Full Text] [Related]
4. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival.
Kaplon RJ; Hochman PS; Michler RE; Kwiatkowski PA; Edwards NM; Berger CL; Xu H; Meier W; Wallner BP; Chisholm P; Marboe CC
Transplantation; 1996 Feb; 61(3):356-63. PubMed ID: 8610340
[TBL] [Abstract][Full Text] [Related]
5. A novel murine model for the assessment of human CD2-related reagents in vivo.
Ding Y; Qin L; Yang Q; Punch JD; Fox DA; Hochman PS; Bromberg JS
J Immunol; 1996 Sep; 157(5):1863-9. PubMed ID: 8757303
[TBL] [Abstract][Full Text] [Related]
6. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras.
Sultan P; Schechner JS; McNiff JM; Hochman PS; Hughes CC; Lorber MI; Askenase PW; Pober JS
Nat Biotechnol; 1997 Aug; 15(8):759-62. PubMed ID: 9255790
[TBL] [Abstract][Full Text] [Related]
7. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.
da Silva AJ; Brickelmaier M; Majeau GR; Li Z; Su L; Hsu YM; Hochman PS
J Immunol; 2002 May; 168(9):4462-71. PubMed ID: 11970990
[TBL] [Abstract][Full Text] [Related]
8. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
9. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
[TBL] [Abstract][Full Text] [Related]
10. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation.
Majeau GR; Whitty A; Yim K; Meier W; Hochman PS
Cell Adhes Commun; 1999; 7(3):267-79. PubMed ID: 10626910
[TBL] [Abstract][Full Text] [Related]
11. Alefacept. Amevive, BG 9273, human LFA-3/Igg fusion protein, LFA 3, LFA 3 TIP LFA 3/CD2, LFA-3/Igg fusion protein, LFA3TIP, recombinant LFA-3/Igg1 human fusion protein, recombinantly engineered LFA-1/Igg1 human fusion protein.
Drugs R D; 2002; 3(1):21-4. PubMed ID: 11881524
[No Abstract] [Full Text] [Related]
12. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
13. Generation of a fusion protein of the extracellular domain of BR3 with the Fc fragment of human IgG1 (sBR3-Fc) in Pichia pastoris as an antagonist for BLyS.
Cao P; Zhang S; Fang Z; Huang H; Bai P; Zhang Q; Luo C
Appl Microbiol Biotechnol; 2008 Feb; 78(2):275-82. PubMed ID: 18189138
[TBL] [Abstract][Full Text] [Related]
14. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation.
de Waal Malefyt R; Yssel H; de Vries JE
J Immunol; 1993 Jun; 150(11):4754-65. PubMed ID: 7684412
[TBL] [Abstract][Full Text] [Related]
15. Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.
Damschroder MM; Kozhich AA; Woods RM; Cheng L; Mullikin BA; Wilson SD; Ulbrandt ND; Bachy CM; Wu H; Suzich JA; Kiener PA; Dall'Acqua WF; White WI
Mol Immunol; 2004 Aug; 41(10):985-1000. PubMed ID: 15302161
[TBL] [Abstract][Full Text] [Related]
16. Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12.
Gollob JA; Li J; Kawasaki H; Daley JF; Groves C; Reinherz EL; Ritz J
J Immunol; 1996 Sep; 157(5):1886-93. PubMed ID: 8757306
[TBL] [Abstract][Full Text] [Related]
17. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice.
Kunzendorf U; Pohl T; Bulfone-Paus S; Krause H; Notter M; Onu A; Walz G; Diamantstein T
J Clin Invest; 1996 Mar; 97(5):1204-10. PubMed ID: 8636431
[TBL] [Abstract][Full Text] [Related]
18. Monocyte-regulated IFN-gamma production in human T cells involves CD2 signaling.
Wingren AG; Dahlenborg K; Björklund M; Hedlund G; Kalland T; Sjögren HO; Ljungdahl A; Olsson T; Ekre HP; Sansom D
J Immunol; 1993 Aug; 151(3):1328-36. PubMed ID: 7687629
[TBL] [Abstract][Full Text] [Related]
19. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
20. A divalent major histocompatibility complex/IgG1 fusion protein induces antigen-specific T cell activation in vitro and in vivo.
Cullen CM; Jameson SC; DeLay M; Cottrell C; Becken ET; Choi E; Hirsch R
Cell Immunol; 1999 Feb; 192(1):54-62. PubMed ID: 10066347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
